1[1]Echt DS,Liebson PR,Mitchell LB,et al. Mortality and morbidity in patients receiving encainide,flecainide or placebo. The cardiac arrhythmia suppression trial[J]. N Engl J Med,1991,324:781-787.
2[2]The Cardiac Arrrhythmia Suppression Trial Ⅱ investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction[J]. N Eng1 J Med,1992,327:227-233.
3[3]Waldo AL,Camm AJ,DeRuyter H,et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction[J]. Lancet,1996,348:7-12.
4[4]Guerra PG,Talajic M,Roy D,et al. Is there a future for antiarrhythmic durg therapy?[J]. Drugs,1998.56:767-781.
5[5]Nattel S. Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs[J]. Cardiovasc Res,1998,37:567-577.
6[6]Wijffels MCEF,Kirchhof CJHJ,Dorland R,et al. Atrial fibrillation begets atrial fibrillation:A study in awake chronically instrumented goats[J]. Circulation,1995,92:1965-1968.
7[7]Xu YQ,Pickoff AS,Clarkson CW. Developmental changes in the effects of lidocaine on sodium channels in rat cardiac myocytes[J]. J Pharmacol Exp Ther, 1992,262:670-676.
8[8]Swynghedauw B. Molecular mechanisms of myocardial remodeling[J]. Physiol Rev,1999,79:215-268.
10[10]Shaw RM,Rudy Y. The vulnarable window for unidirectional block in cardiac tissue:Characterization and dependence on membrane excitability and intercellular coupling[J]. J Cardiovasc Electrophysiol,1995,6:115-131.
3Epstein AE, Bigger JT, Wyse DG, et al. Events in the cardiac arrhythmia suppression trial (CAST): Mortality in the entire population enrolled [J ].J Am Coll Cardiol , 19 91,18 : 14- 19.
4徐叔云.药理实验方法学[M].北京：人民卫生出版社,1992.445.
5Friese J,Gleitz J,Gutser UT,et al.Aconitum sp.alkaloids:the modulation of voltage-dependent Na+ channel,toxicity and antinociceptive properties[J].Eur J Pharmacol,1997,337 (2 -3):165-174.
